Qalsody 100 MG/15 ML vial 15ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEA4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,978
Award facts
- Contract value 100% obligated
- $21,978.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,978.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of QALSODY 100 mg/15 mL vials. This firm fixed-price delivery order, issued on December 8, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to establish multiple regional prime vendor contractors to support recurring medical supply needs of Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated substantial contracting activity through numerous delivery orders issued by the DLA's Medical Supply Chain division. The contractor's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning the company to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system. The PPV-G GEN V contract, which became effective on November 13, 2025, is structured with a 30-month base period and three 30-month option periods extending through December 31, 2036, enabling DMS Pharmaceutical Group to serve as a regional pharmaceutical supplier supporting global Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FMEA4?
SPE2DR26FMEA4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FMEA4 worth?
The government has obligated $21,978 on SPE2DR26FMEA4.
Is contract SPE2DR26FMEA4 an order under another contract?
Yes. SPE2DR26FMEA4 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEA4 competed?
The extent of competition for SPE2DR26FMEA4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award